Late-onset fatal Epstein-Barr virus-associated hemophagocytic syndrome following cord blood cell transplantation for adult acute lymphoblastic leukemia

International Journal of Hematology

Volumn 84, Issue 5, 2006, Pages 445-448

  Kawabata, Yoshinari ^a   Hirokawa, Makoto ^a   Saitoh, Yoshinobu ^a   Kosugi, Shigeki ^a   Yoshioka, Tomoko ^a   Fujishima, Masumi ^a   Fujishima, Naohito ^a   Kameoka, Yoshihiro ^a   Saitoh, Hirobumi ^a   Kume, Masaaki ^a   Takahashi, Naoto ^a   Sawada, Ken Ichi ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CBT; EBV; HPS; Late onset; PTLD

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DOXORUBICIN; EPSTEIN BARR VIRUS ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; PREDNISOLONE; TACROLIMUS; VINCRISTINE; VIRUS CAPSID ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW DEPRESSION; BONE MARROW EXAMINATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CAUSE OF DEATH; CORD BLOOD STEM CELL TRANSPLANTATION; CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EPSTEIN BARR VIRUS; FATALITY; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HEMOPHAGOCYTIC SYNDROME; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER DYSFUNCTION; LIVER FAILURE; LOW DRUG DOSE; MACROPHAGE; PANCYTOPENIA; PHAGOCYTE; PROPHYLAXIS; VIRUS TITRATION;

ACYCLOVIR; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BONE MARROW DISEASES; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HEMATOPOIESIS; HEMORRHAGE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN G; LEUKEMIA, LYMPHOCYTIC, ACUTE; LIVER FAILURE; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; METHYLPREDNISOLONE; TIME FACTORS; TRANSPLANTATION CHIMERA;

EID: 33845991158     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06101     Document Type: Article

References (33)

1. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus lymphoproliferation after blood marrow transplantation. Blood. 1988;72:520-529.
2. Lucas KG, Pollok KE, Emanuel DI. Post-transplant Epstein-Barr virus induced lymphoproliferative disorders. Leuk Lymphoma. 1997;25:1-8.
3. O'Relly R, Small T, Papadopoulos E, Lucas K, Lacerda J, Koulova L. Biology and adoptive cell therapy of Epstein-Barr virus associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev. 1997;157:195-216.
4. Knowles DM. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol. 1999;12:325-342.
5. Walker RC, Marshall WF, Strickler J, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis. 1995;20:1346-1353.
6. Nalesnik MA. The diverse pathology of post-transplant assessment of the risk of lymphoproliferative disorders: the importance of a standardized approach. Transpl Infect Dis. 2001;3:88-96.
7. Leblond V, Davi F, Charlotte F, et al. Post-transplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol. 1998;16:2052-2059.
8. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: multi-institutional study. Blood. 1999;94:2208-2216.
9. Gratama JW. Epstein-Barr virus infections in bone marrow transplantation recipients. In: Forman SJ, Blume KG, Thomas ED, eds. Bone Marrow Transplantation. Boston, Mass: Blackwell Scientific Publications: 1994:429-442.
10. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol. 2002;44:259-272.
11. Sirvent N, Reviron D, de Lamballerie X, Michel G. First report of Epstein-Barr virus lymphoproliferative disease after cord blood transplantation. Bone Marrow Transplant. 2000;25:120-121.
12. Ohga S, Kanaya Y, Maki H, et al. Epstein-Barr virus-associated lymphoproliferative disease after a cord blood transplantation for Diamond-Blackfan anemia. Bone Marrow Transplant. 2000;25:209-212.
13. Haut PR, Kovarik P, Shaw PH, Walterhouse D, Jenson HB, Kletzel M. Detection of EBV in the cord blood donor for a patient developing Epstein-Barr virus-associated lymphoproliferative disorder following mismatched unrelated umbilical cord blood transplantation. Bone Marrow Transplant. 2001;27:761-765.
14. Barker JN, Martin PL, Coad JE, et al. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated donor umbilical cord blood transplant recipients. Biol Blood Marrow Transplant. 2001;7:395-399.
15. Meyer-Bahlburg A, Winkler J, Meerbach A, et al. Fatal late-onset EBV-associated post transplant lymphoproliferative disease after umbilical cord blood transplantation due to persistent mixed chimerism and severe delay in T-cell recovery in a patient with Omenn's syndrome. Bone Marrow Transplant. 2004;34:283-284.
16. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood. 1995;85:552-565.
17. Knowles D. Immunodeficiency-associated lymphoproliferative disorders Mod Pathol. 1999;12:200-217.
18. Wagner HJ, Rooney CM, Heslop HE. Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8:1-8.
19. Paya CV, Fung JJ, Nalesnik, et al, for the ASTS/ASTP EBV-PTLD Task Force and the Mayo Clinic organized International Consensus Development Meeting on Epstein-Barr Virus-Induced Posttransplant Lymphoproliferative Disorders (PTLD). Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Transplantation. 1999;68:1517-1525.
20. + T-cell restoration. Blood. 2002;100:2341-2348.
21. Imashuku S, Kuriyama K, Teramura T, et al. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol. 2001;19:2665-2673.
22. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusion of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New Engl J Med. 1994;330:1185-1191.
23. Rooney CM, Smith CA, Ng CY, et al. Use of gene modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet. 1995;345:9-13.
24. Hoshino Y, Kimura H, Tanaka N, et al. Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogeneic stem cell transplantation. Br J Haematol. 2001;115:105-111.
25. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionatcd whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood. 2001;97:1165-1171.
26. Ohga S, Kubo E, Nomura, et al. Quantitative monitoring of circulating Epstein-Barr virus DNA for predicting the development of posttransplantation lymphoproliferative disease. Int J Hematol. 2000;73:323-326.
27. Kuchnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000;95:1502-1505.
28. Faye A, Quartier P, Reguerre Y, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol. 2001;115:112-118.
29. Imashuku S, Hibi S, Ohara T, et al, for the Histiocyte Society. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Blood. 1999;93:1869-1874.
30. Imashuku S. Advances in the management of hemophagocytic lymphohistiocytosis. Int J Hematol. 2000;72:1-11.
31. Moretta A, Comoli P, Montagna D, et al. High frequency of Epstein-Barr virus (EBV) lymphoblastoid cell line-reactive lymphocytes in cord blood: evaluation of cytolytic activity and IL-2 production. Clin Exp Immunol. 1997;107:312-320.
32. + Epstein-Barr virus-specific cytotoxic T-lymphocytes from human umbilical cord blood. Cell Immunol. 1999;195:81-88.
33. Yazaki M, Takahashi T, Ho Y, Ito T, Mori C, Wada Y. Generation of HLA-A2 subtype specific cytotoxic T lymphocytes from cord blood used for cord blood stem cell transplantation. Bone Marrow Transplant. 2000;26:451-453.